Despite the advances that have been made with atypical antipsychotics indicated for the treatment of schizophrenia (SCZ), significant safety and efficacy concerns persist with these D2 blockers. Inadequate response to these treatments is common. Several emerging agents are undergoing phase 3 clinical trials. These new treatments possess unique mechanisms of action, encouraging efficacy profiles across positive, negative, and cognitive domains and favorable safety profiles that offer new hope for those living with SCZ. This educational series will cover accurately identifying individuals, including those in unique patient populations, who may benefit from switching to or augmentation with an emerging treatment option, how and when to incorporate switching or augmentation strategies, and how to integrate new therapies into current clinical practice.
Schizophrenia: Evidence-based Approaches to Integrating Emerging Treatments Into Clinical Practice
Be part of the knowledge.™Schizophrenia: Evidence-based Approaches to Integrating Emerging Treatments Into Clinical Practice
Overview
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all educational programs.
The following faculty have disclosed:
Christoph U Correll, MD, chair for this educational event, receives a research grant and manages the fund for Janssen and Takeda; receives ownership interest from Cardio Diagnostics, Mindpax, LB Pharm, and Quantic; receives royalties from UpToDate; and receives consulting fees from AbbVie, Acadia, Alkermes, Allergan, Angelini, Aristo, Boehringer-Ingelheim, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Denovo, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Merck, Mindpax, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Newron, Noven, Novo Nordisk, Otsuka, Pharmabrain, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Seqirus, SK Life Science, Sunovion, Sun Pharma, Supernus, Takeda, Teva, and Viatris.
Leslie Citrome, MD, MPH, faculty for this educational event, receives ownership interest (in the form of a small number of shares of common stock) from the following: Bristol-Myers Squibb, Eli Lilly, J & J, Merck, Pfizer purchased > 10 years ago; receives stock options from Reviva; receives royalties from Taylor & Francis (Editor-in-Chief, Current Medical Research and Opinion, 2022-present), Wiley (Editor-in-Chief, International Journal of Clinical Practice, through end of 2019), UpToDate (reviewer), Springer Healthcare (book), Elsevier (Topic Editor, Psychiatry, Clinical Therapeutics); receives consulting fees from AbbVie/Allergan, Acadia, Adamas, Alkermes, Angelini, Astellas, Avanir, Axsome, BioXcel, Boehringer Ingelheim, Cadent Therapeutics, Cerevel, Clinilabs, COMPASS, Eisai, Enteris BioPharma, HLS Therapeutics, Idorsia, INmune Bio, Impel, Intra-Cellular Therapies, Janssen, Karuna, Lundbeck, Lyndra, Medavante-ProPhase, Marvin, Merck, Mitsubishi-Tanabe Pharma, Neurocrine, Neurelis, Novartis, Noven, Otsuka, Ovid, Praxis, Recordati, Relmada, Reviva, Sage, Sunovion, Supernus, Teva, University of Arizona, Vanda, and one-off ad hoc consulting for individuals/entities conducting marketing, commercial, or scientific scoping research; is a speaker for AbbVie/Allergan, Acadia, Alkermes, Angelini, Axsome, BioXcel, Eisai, Idorsia, Intra-Cellular Therapies, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Recordati, Sage, Sunovion, Takeda, Teva, and CME activities organized by medical education companies such as Medscape, NACCME, NEI, Vindico, and Universities and Professional Organizations/Societies.Planners and Managers Disclosure List
The following planners/reviewers/managers have disclosed:
Canan Schumann, PharmD/PhD, planner for this educational event, has no relevant financial relationships with ineligible companies.
William Mencia, MD, FACEHP, CHCP, reviewer for this educational event, has no relevant financial relationships with ineligible companies.
Total CME, LLC., planners, and managers have no relevant commercial relationships to disclose.
All the relevant financial relationships for these individuals have been mitigated.Learning Objectives
After participating in this educational activity, participants should be better able to:
- Identify the limitations of current D2 antipsychotic medications in treating SCZ, with a focus on efficacy limitations and safety/side effect considerations
- Increase awareness in accurately identifying individuals who may benefit from switching to or augmentation with new and emerging therapies
- Educate regarding how and when to incorporate switching or augmentation strategies into antipsychotic medication management of patients with SCZ, including special populations
- Educate regarding the considerations of integrating new therapies into current clinical practice as a monotherapy, switching option, or augmentation strategy
- Provide expert analysis of current clinical trial data of emerging treatment options, particularly regarding their efficacy in controlling negative and positive symptoms and cognitive function
Target Audience
This activity has been designed to meet the educational needs of the interprofessional team, which includes clinicians who specialize in Psychiatry, as well as other healthcare providers involved in managing patients with Schizophrenia.
Accreditation and Credit Designation Statements
In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and Total CME, LLC. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credits for learning and change.
Achknowledgment
This activity is supported by an independent educational grant from Karuna Therapeutics, Inc. (recently acquired by Bristol Myers Squibb).
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Total CME, LLC. This presentation is not intended to define an exclusive course of patient management; the participant should use their clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of MedEd On The Go, you are subject to the terms and conditions of use, including copyright and licensing restrictions, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date:
Facebook Comments